下肢血液透析通路中动静脉移植物与动静脉瘘的比较
该回顾性研究纳入2006至2022年在本机构接受股部血液透析通路的91例患者,比较股部静脉转位动静脉瘘(AVF,41例)与动静脉移植物(AVG,50例)的通畅率。结果显示AVF组在辅助初级通畅率和次级通畅率上均优于AVG组,而初级通畅率两组无显著差异。股部血管通路在上肢通路耗尽时是可用的替代选择。
要点
- 股部AVF组12和24个月辅助初级通畅率分别为93%和85%,高于AVG组的82%和73%(P < .001)。
- 股部AVF组12和24个月次级通畅率分别为97%和94%,高于AVG组的84%和82%(P = .001)。
- 对侧股静脉置管史和感染对次级通畅率有不利影响(HR 2.95,95%CI 1.43-6.07,P = .002)。
核心结论
- 下肢血液透析通路可获得良好的次级通畅率和患者生存率,股部AVF在辅助初级通畅率和次级通畅率上优于AVG。
- 当上肢血管通路选项耗尽时,股部血管通路是可用的替代选择。
研究设计与样本
- 回顾性研究,纳入2006年至2022年在本机构接受股部血液透析通路的91例患者(平均年龄63 ± 11岁,57例男性),其中41例为股部AVF,50例为股部AVG。
- 采用Kaplan-Meier生存分析评估通畅率,通过Cox回归模型分析影响通畅率的危险因素,并对AVF与AVG进行比较分析。
主要发现
- 总体12个月和24个月初级通畅率分别为48%和27%,辅助初级通畅率分别为87%和78%,次级通畅率分别为90%和89%。
- 股部AVF组12和24个月初级通畅率分别为50%和29%,辅助初级通畅率分别为93%和85%,次级通畅率分别为97%和94%。
- 股部AVG组12和24个月初级通畅率分别为44%和22%,辅助初级通畅率分别为82%和73%,次级通畅率分别为84%和82%。
- 股部AVF与AVG的初级通畅率无显著差异(P = .858),但AVF组辅助初级通畅率更高(P < .001),次级通畅率也更高(P = .001)。
- 对侧股静脉置管史和感染对次级通畅率有不利影响(HR 2.95,95%CI 1.43-6.07,P = .002)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although upper arm hemodialysis access is preferred due to better patency and lower complication rates, femoral access remains necessary for certain patients. This study evaluates the patency rates of femoral hemodialysis access, specifically comparing femoral vein transposition arteriovenous fistula (AVF) and arteriovenous graft (AVG), and identifying factors affecting patency. METHODS: We conducted a retrospective review of patients who received femoral access at our institution from 2006 to 2022. Patency rates were assessed using Kaplan-Meier survival analysis. Risk factors influencing patency were examined through Cox regression modeling, and a comparative analysis between AVF and AVG was performed. RESULTS: Ninety-one patients received femoral hemodialysis access (mean age, 63 ± 11 years; 57 males). Forty-one had AVF, and 50 had AVG. The overall 12-month and 24-month primary patency rates were 48% and 27%, assisted primary patency rates were 87% and 78%, and secondary patency rates were 90% and 89%. Subgroup analysis showed that femoral AVFs had 50% and 29% primary, 93% and 85% assisted primary, and 97% and 94% secondary patency at 12 and 24 months, respectively. Femoral AVGs demonstrated 44% and 22% primary, 82% and 73% assisted primary, and 84% and 82% secondary patency at 12 and 24 months. There was no significant difference in primary patency between femoral AVFs and AVGs (P = .858). However, the femoral AVF group had higher assisted primary patency (P < .001) and secondary patency (P = .001). Previous femoral vein catheterization on the contralateral side and infection adversely affected secondary patency (hazard ratio, 2.95; 95% confidence interval, 1.43-6.07; P = .002). CONCLUSIONS: Lower extremity hemodialysis access yields excellent secondary patency and patient survival rates, with AVF showing superior assisted primary patency and secondary patency compared with AVG. Femoral vascular access is a viable alternative when upper extremity options are exhausted.
引用
- Jeong J, Choi SY, Kim YJ, et al. A comparison of arteriovenous grafts and fistulas in lower extremity hemodialysis procedures. J Vasc Surg. 2025. PMID: 40058472. doi:10.1016/j.jvs.2025.03.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。